Once-yearly zoledronic acid in hip fracture prevention.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 2685236)

Published in Clin Interv Aging on May 14, 2009

Authors

Oddom Demontiero1, Gustavo Duque

Author Affiliations

1: Aging Bone Research Program, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia.

Articles cited by this

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20

Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29

Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA (2001) 6.44

Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32

Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest (2005) 5.19

A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92

Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71

Risk of subsequent fracture after low-trauma fracture in men and women. JAMA (2007) 4.19

Epidemiology of osteoporotic fractures. Osteoporos Int (2004) 3.60

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 3.13

Osteoporosis: a still increasing prevalence. Bone (2006) 2.89

Bisphosphonates: mechanisms of action. J Clin Invest (1996) 2.83

Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med (2000) 2.62

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res (2000) 2.32

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29

Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med (2003) 2.19

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol (2002) 2.03

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97

Survival after hip fracture. Osteoporos Int (2005) 1.93

Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol (2003) 1.92

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res (1994) 1.84

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys (2000) 1.82

Bisphosphonates: from bench to bedside. Ann N Y Acad Sci (2006) 1.82

Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75

Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am (2002) 1.72

Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72

A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone (2007) 1.68

Influence of health status and the timing of surgery on mortality in hip fracture patients. Am J Orthop (Belle Mead NJ) (1997) 1.62

Underuse of osteoporosis medications in elderly patients with fractures. Am J Med (2003) 1.57

Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int (2006) 1.49

Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis (1998) 1.48

The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab (2005) 1.43

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol (2002) 1.38

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone (2001) 1.35

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum (2001) 1.31

Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res (2003) 1.31

Osteoporosis epidemiology update. Curr Rheumatol Rep (2008) 1.24

Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res (2008) 1.21

Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab (2007) 1.10

Bisphosphonates and osteonecrosis of the jaw. Med J Aust (2005) 1.03

Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int (2003) 1.01

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol (2001) 1.00

Post-fracture management of patients with hip fracture: a perspective. Curr Med Res Opin (2008) 0.99

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med (2008) 0.97

Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 0.96

Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am (2006) 0.96

Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev (2003) 0.95

Prevention of osteoporotic fractures in the elderly. Am J Med (2005) 0.94

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int (2007) 0.92

Zoledronic acid: a new parenteral bisphosphonate. Clin Ther (2003) 0.91

Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res (1998) 0.83

Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine (2007) 0.81

The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab (2000) 0.80

Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int J Clin Pract (2007) 0.77

The underuse of therapy in the secondary prevention of hip fractures. Drugs Aging (2002) 0.76

Intravenous zoledronic acid reduced new clinical fractures and deaths in patients who had recent surgery for hip fracture. ACP J Club (2008) 0.76

Prevention and treatment of senile osteoporosis and hip fractures. Minerva Med (2009) 0.76

Articles by these authors

Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol (2008) 3.43

Age-related bone loss: old bone, new facts. Gerontology (2002) 1.38

Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis (2013) 1.09

Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med (2009) 1.08

Effect of lamin A/C knockdown on osteoblast differentiation and function. J Bone Miner Res (2009) 1.07

Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med (2005) 1.04

Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Mol Aspects Med (2005) 1.03

Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02

Decreased bone formation and osteopenia in lamin a/c-deficient mice. PLoS One (2011) 0.99

Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology (2009) 0.98

Accelerated features of age-related bone loss in zmpste24 metalloproteinase-deficient mice. J Gerontol A Biol Sci Med Sci (2009) 0.90

Age-related changes in lamin A/C expression in cardiomyocytes. Am J Physiol Heart Circ Physiol (2007) 0.89

Fat and bone interactions. Curr Osteoporos Rep (2014) 0.89

Mechanisms of palmitate-induced lipotoxicity in human osteoblasts. Endocrinology (2013) 0.87

Is collectionism a diagnostic clue for Diogenes syndrome? Int J Geriatr Psychiatry (2005) 0.86

Health care for older persons in Colombia: a country profile. J Am Geriatr Soc (2009) 0.86

Mechanisms of palmitate-induced cell death in human osteoblasts. Biol Open (2013) 0.85

The orthogeriatrics model of care: systematic review of predictors of institutionalization and mortality in post-hip fracture patients and evidence for interventions. J Am Med Dir Assoc (2012) 0.85

Seasonal variance in serum levels of vitamin d determines a compensatory response by parathyroid hormone: study in an ambulatory elderly population in Quebec. Gerontology (2006) 0.85

Supplementation with vitamin D and calcium in long-term care residents. J Am Med Dir Assoc (2010) 0.85

Severe bone changes in a case of Hutchinson-Gilford syndrome. Ann Genet (2002) 0.85

Gait disorders are associated with non-cardiovascular falls in elderly people: a preliminary study. BMC Geriatr (2005) 0.85

Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL/6J mice. Exp Gerontol (2009) 0.84

Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascul Pharmacol (2009) 0.83

Validation of noninvasive quantification of bone marrow fat volume with microCT in aging rats. Exp Gerontol (2011) 0.82

The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis. Stem Cells (2015) 0.82

Lamin A/C deficiency is associated with fat infiltration of muscle and bone. Mech Ageing Dev (2011) 0.82

Weight loss on stimulant medication: how does it affect body composition and bone metabolism? - A prospective longitudinal study. Int J Pediatr Endocrinol (2012) 0.81

Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis. J Am Med Dir Assoc (2013) 0.80

Interferon gamma inhibits adipogenesis in vitro and prevents marrow fat infiltration in oophorectomized mice. Stem Cells (2012) 0.79

An old friend in a new light: the role of osteocalcin in energy metabolism. Cardiovasc Ther (2011) 0.79

Inhibition of Protein Farnesylation Arrests Adipogenesis and Affects PPARgamma Expression and Activation in Differentiating Mesenchymal Stem Cells. PPAR Res (2007) 0.78

Biochemical changes induced by strontium ranelate in differentiating adipocytes. Biochimie (2012) 0.77

Conjugated linoleic acid is related to bone mineral density but does not affect parathyroid hormone in men. Nutr Res (2012) 0.77

Moving beyond static body composition paradigms to assessments of change, plasticity, and function. J Am Geriatr Soc (2010) 0.77

Differing approaches to falls and fracture prevention between Australia and Colombia. Clin Interv Aging (2013) 0.75

Role of the nuclear envelope in the pathogenesis of age-related bone loss and osteoporosis. Bonekey Rep (2012) 0.75

In defence of calcium. Med J Aust (2011) 0.75

Use of analgesics in elderly nursing home residents. J Am Geriatr Soc (2005) 0.75

Chronic hypercalcemia as a reversible cause of cognitive impairment: improvement after a single administration of pamidronate. J Am Geriatr Soc (2005) 0.75

Yield and cost-effectiveness of laboratory testing to identify metabolic contributors to falls and fractures in older persons. Arch Osteoporos (2015) 0.75

[Osteoporosis in the elderly]. Presse Med (2006) 0.75

[Senile osteoporosis: an update]. Rev Esp Geriatr Gerontol (2011) 0.75